Celgene takes 4.7% stake in Mesoblast and options up first rights for 6 months on Mesoblast's phase 3 program on GVHD , plus other programs. This is interesting for Mesoblast as TEVA already has a close to 20% stake in Mesoblast and co-partners the Mesoblast phase 3 program on chronic congestive heart failure .
http://seekingalpha.com/article/3066746-celgenes-play-in-cell-based-therapy-regenerative-medicine-is-very-good-news-for-mesoblast?source=feed_all_articles
http://seekingalpha.com/article/3066746-celgenes-play-in-cell-based-therapy-regenerative-medicine-is-very-good-news-for-mesoblast?source=feed_all_articles
No comments:
Post a Comment